Patents by Inventor Colin O'Bryan

Colin O'Bryan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11352355
    Abstract: Disclosed are chemical entities which are inhibitors of spleen tyrosine kinase (SYK), namely, chemical entities comprising 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one and certain solid state forms thereof. Also disclosed are methods of using the chemical entities to treat disorders such as a cancer.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: June 7, 2022
    Assignee: Calithera Biosciences, Inc.
    Inventors: Rongliang Chen, Tomonori Ichibakase, Chunrong Ma, Christopher F. Matthews, Hajime Motoyoshi, Colin O'Bryan, Kentaro Yaji, Naoki Yoshikawa
  • Publication number: 20200339573
    Abstract: Disclosed are chemical entities which are inhibitors of spleen tyrosine kinase (SYK), namely, chemical entities comprising 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one and certain solid state forms thereof. Also disclosed are methods of using the chemical entities to treat disorders such as a cancer.
    Type: Application
    Filed: May 8, 2020
    Publication date: October 29, 2020
    Inventors: Rongliang Chen, Tomonori Ichibakase, Chunrong Ma, Christopher F. Matthews, Hajime Motoyoshi, Colin O'Bryan, Kentaro Yaji, Naoki Yoshikawa
  • Patent number: 10676473
    Abstract: Disclosed are chemical entities which are inhibitors of spleen tyrosine kinase (SYK), namely, chemical entities comprising 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one and certain solid state forms thereof. Also disclosed are methods of using the chemical entities to treat disorders such as a cancer.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: June 9, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Rongliang Chen, Tomonori Ichibakase, Chunrong Ma, Christopher F. Matthews, Hajime Motoyoshi, Colin O'Bryan, Kentaro Yaji, Naoki Yoshikawa
  • Publication number: 20160176869
    Abstract: Disclosed are chemical entities which are inhibitors of spleen tyrosine kinase (SYK), namely, chemical entities comprising 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one and certain solid state forms thereof. Also disclosed are methods of using the chemical entities to treat disorders such as a cancer.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 23, 2016
    Inventors: Rongliang Chen, Tomonori ICHIBAKASE, Chunrong MA, Christopher MATTHEWS, Hajime MOTOYOSHI, Colin O'BRYAN, Kentaro YAJI, Naoki YOSHIKAWA
  • Patent number: 9181280
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: November 10, 2015
    Assignee: PHARMACYCLICS LLC
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader
  • Publication number: 20140221667
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Application
    Filed: April 11, 2014
    Publication date: August 7, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Daniel A. DICKMAN, Dange Vijay KUMAR, Colin O'BRYAN, Roopa RAI, William Dvorak SHRADER
  • Patent number: 8729117
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: May 20, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader
  • Publication number: 20140080879
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: PHARMACYCLICS, INC.
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader
  • Publication number: 20130197229
    Abstract: Disclosed are methods, reagents, and intermediates useful for making azaindazole derivatives, which may be used to modulate Glucokinase. The disclosed methods and materials are generally useful for making halo-esters and sulfonyl-substituted compounds.
    Type: Application
    Filed: October 13, 2011
    Publication date: August 1, 2013
    Inventors: Christopher Matthews, Colin O'Bryan, David Paul Provencal
  • Patent number: 8415328
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: April 9, 2013
    Assignee: Pharmacyclics, Inc
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader, Kieron Wesson
  • Publication number: 20110207939
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Application
    Filed: May 3, 2011
    Publication date: August 25, 2011
    Applicant: Pharmacyclics, Inc.
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader, Kieron Wesson
  • Publication number: 20080275250
    Abstract: The present invention relates to novel inhibitors or Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Application
    Filed: June 2, 2005
    Publication date: November 6, 2008
    Applicant: PHARMACYCLICS, INC.
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader, Kieron Wesson